Almac

The company plans to outlicense the assay, developed using a custom Affymetrix microarray, to an interested partner.

The collaboration will streamline patient sample analysis to determine whether they should be included in clinical trials for molecularly targeted treatment. 

The partners plan to develop a computational platform that automates pipelines and processes for biomarker discovery, drug recovery and repositioning, and more.

The deal allows UK-based Almac to develop NGS assays on the Illumina MiSeqDx instrument.

The firms are developing a gene expression RSPO3 CLIA assay to select patients in the clinical development of OncoMed's therapeutic.

NEW YORK (GenomeWeb) — Pharmaceutical companies are jockeying to formulate companion diagnostics strategies that involve a new microarray-based assay developed by Almac Diagnostics, according to the company.

NEW YORK (GenomeWeb) — Almac Diagnostics has developed a microarray-based test that can be used to determine which ovarian cancer patients will have a good prognosis following chemotherapy.

NEW YORK (GenomeWeb News) – Almac's diagnostics business today said that it has received a clinical laboratory permit from New York, allowing it to receive clinical samples from the state for clinical testing and trial management.

Almac Diagnostics said this week that a group led by partner Precision Therapeutics has independently validated Almac's ColDx test for stage II colorectal cancer recurrence ahead of its full commercialization in the US.

Pages

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.